Journal of Affective Disorders
Volume 81, Issue 1 , Pages 67-72 , July 2004

Reboxetine adjunct for partial or nonresponders to antidepressant treatment

  • Gabriel Rubio

      Affiliations

    • Psychiatry Service, “La Paz” University Hospital, Madrid, Spain
    • ,
  • Luis San

      Affiliations

    • “Benito Menni” Mental Health Care Institute, Sant Boi, Barcelona, Spain
    • ,
  • Francisco López-Muñoz

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +34-91-7248207; fax: +34-91-7248205.
    • Neuropsychopharmacology Unit, Pharmacology Department, Faculty of Medicine, University of Alcalá, C/Juan Ignacio Luca de Tena, 8, 28027 Madrid, Spain
    • ,
  • Cecilio Alamo

      Affiliations

    • Neuropsychopharmacology Unit, Pharmacology Department, Faculty of Medicine, University of Alcalá, C/Juan Ignacio Luca de Tena, 8, 28027 Madrid, Spain

Received 28 February 2003 ,Revised 4 August 2003 ,Accepted 8 August 2003.

References 

  1. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr. Clin. North Am. 1996;19:371–386
  2. Amsterdam JD, Garcı́a-España F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress. Anxiety. 1997;5:84–90
  3. Berman RM, Narasimhan M, Charney DS. Treatment-refractory depression: definitions and characteristics. Depress. Anxiety. 1997;5:154–164
  4. Bodkin JA, Lasser RA, Wines JD, et al.  Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J. Clin. Psychiatry. 1997;58:137–145
  5. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int. Clin. Psychopharmacol. 1994;9(Suppl. 2):5–10
  6. Carpenter LL, Jocic Z, Hall JM, et al.  Mirtazapine augmentation in the treatment of refractory depression. J. Clin. Psychiatry. 1999;60:45–49
  7. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol. Psychiatry. 2002;51:183–188
  8. Devarajan S, Dursun SM. Citalopram plus reboxetine in treatment-resistant depression. Can. J. Psychiatry. 2000;45:489–490
  9. Fava M. New approaches to the treatment of refractory depression. J. Clin. Psychiatry. 2000;61(Suppl. 1):26–32
  10. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 1996;19:179–200
  11. Fava M, Rosenbaum JF, McGrath PJ, et al.  Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am. J. Psychiatry. 1994;151:1372–1374
  12. Fawcett J. Antidepressants: partial response in chronic depression. Br. J. Psychiatry. 1994;165:37–41
  13. Hirschfeld RM, Montgomery SA, Aguglia E, et al.  Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry. 2002;63:826–837
  14. Joffe RT. Substitution therapy in patients with major depression. CNS Drugs. 1999;11:175–180
  15. Katona C, Bercoff E, Chiu E, et al.  Reboxetine versus imipramine in the treatment of elderly patents with depressive disorders: a double-blind randomised trial. J. Affect. Disord. 1999;55:203–213
  16. Kennedy SH, McCann SM, Masellis M, et al.  Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J. Clin. Psychiatry. 2002;63:181–186
  17. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355:911–918
  18. Lam RW, Wan DDC, Cohen NL, et al.  Combining antidepressants for treatment-resistant depression: a review. J. Clin. Psychiatry. 2002;63:685–693
  19. Lucca A, Serretti A, Smeraldi E. Effect of reboxetine augmentation in SSRI resistant patients. Human Psychopharmacol. Clin. Exp. 2000;15:143–145
  20. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J. Psychopharmacol. 1997;1(Suppl. 4):9–15
  21. Nelson JC. Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress. Anxiety. 1998;7(Suppl. 1):5–6
  22. Nelson JC. Augmentation strategies in depression. J. Clin. Psychiatry. 2000;61(Suppl. 2):13–19
  23. Nelson JC, Mazure CM, Bowers MB, et al.  A preliminary open study if the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch. Gen. Psychiatry. 1991;48:303–307
  24. Nierenberg AA, Amsterdam JD. Resistant depression: definition and treatment approaches. J. Clin. Psychiatry. 1990;51:S39–S47
  25. Sackeim HA. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry. 2001;62(Suppl. 16):10–17
  26. Serretti A, Lucca A, Cusin C, Smeraldi E. Associazione di reboxetina nella depressione resistente a SSRI G. Ital. Psicopatol. 2001;7:9–14
  27. Sokolov STH, Joffe RT. Practical guidelines for combination drug therapy of treatment-resistant depression. CNS Drugs. 1995;4:341–350
  28. Stanley B. An integration of ethical and clinical considerations in the use of placebos. Psychopharmacol. Bull. 1988;24:180–220
  29. Szegesi A, Wetzel H, Leal M, et al.  Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. J. Clin. Psychiatry. 1996;57:257–264
  30. Tanum L. Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr. Scand. 2000;101(Suppl. 402):37–40
  31. Thase ME, Rush AJ. Treatment-resistant depression. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995;p. 1081–1097
  32. Wong EHF, Sonders MS, Amara SG, et al.  Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry. 2000;47:818–829

PII: S0165-0327(03)00202-7

doi: 10.1016/j.jad.2003.08.001

Journal of Affective Disorders
Volume 81, Issue 1 , Pages 67-72 , July 2004

Article Tools